8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


        Date of Report (Date of earliest event reported): August 18, 2004

                           APPLIED DNA SCIENCES, INC.
                      ------------------------------------

             (Exact name of registrant as specified in its charter)


          Nevada                      290519                    59-2262718
- ----------------------------       -----------             -------------------
(State or other jurisdiction        Commission                 (IRS Employer
     of Incorporation)              File Number              Identification No.)


    9229 Sunset Boulevard Los Angeles, CA Ste 830               90069
    ---------------------------------------------             ---------
     (Address of principal executive offices)                 (Zip Code)


       Registrant's Telephone Number, including area code: (310) 860-1362


         (Former name or former address, if changed since last report.)


Item 5.02  Appointment of Principal Officers

On August 2, 2004, Applied DNA Sciences, Inc. (the "Company") appointed Karin
Lise Klemm to the position of Chief Operating Officer and Secretary. In that
capacity, Ms. Klemm will oversee the day to day operations of the Company. Ms.
Klemm continues to serve as President of Poly Pacific Entertainment, Inc., an
entertainment company based in Beverly Hills, where she began her employ in that
role in August of 1999. Since August of 2003, Ms. Klemm has served as Chief
Executive Officer to Uncensored Music Network, Inc., also an entertainment
company. Previously, from 1997 through 2000, Ms. Klemm was a branch manager of
RH11, an executive search firm in Los Angeles, California.

Item 7.01 Regulation FD Disclosure

On August 18, 2004, the Company mailed a letter to its record shareholders. The
letter referenced specific agreements recently entered into but not yet
announced. Additionally, the letter disclosed the Company's progress in
furthering its business plan. In accordance with Regulation FD, this current
report is being filed to publicly disclose all information that was provided to
the record shareholders of Applied DNA in its August 18th letter. This report
under Item 7.01 is not deemed an admission as to the materiality of any
information in this report that is required to be disclosed solely by Regulation
FD.

Item 9.01 Financial Statements and Exhibits

(c)   Exhibits. The following document is filed as an exhibit to this report:

      99.1     Letter to record shareholders dated August 18, 2004


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                  APPLIED DNA SCIENCES, INC.



                                  /S/ Peter Brockelsby
                                  ------------------------------
                                  Peter Brockelsby, President

EX-99.1 CHARTER

Exhibit 99.1

APPLIED DNA SCIENCES, INC.                9229 West Sunset Blvd, Suite 830
                                          Los Angeles, CA  90069
                                          Tel. 310-860-1129 Fax 310-860-1303


TO OUR SHAREHOLDERS


August 18, 2004

Dear Shareholders,

As your Company's new president, I take this opportunity to introduce myself and
bring you up to date on what has been a challenging and productive year for your
Company. Those of you who were among our original shareholders have seen your
interests decline. That is why a new management team is bringing new thinking,
new direction and increased value to APDN.

I'm pleased to tell you that in the last 8 weeks, much has happened to correct
the imbalances that have led to the diminution of your Company's stock price. A
new management and advisory team have been installed. A great deal of strategic
planning and reorganization has been implemented to improve the future of the
stock, generate revenues and increase the valuation of the company.

We now have in place a professional team competent to deliver proper legal and
financial stability. We are successfully completing initiatives to secure and
expand sales through alliances with strategic industry partners. These endeavors
will be funded in part from operations and will also require additional capital
funding, which the Company is successfully raising. The Company will continue to
secure additional working capital to meet its operating requirements and growth
plans.

In the weeks ahead, we will share with you the many exciting developments now
under way with Fortune 500 companies and with U.S. and Foreign Government
institutions. Last week we executed an agreement to develop new products with
Sun Chemical, a four billion dollar global company and the largest ink producer
in the world. Their inks go into everything: security products for financial
institutions, governments, currency, packaging, consumer products,
pharmaceuticals, DVDs, CDs, auto parts, cosmetics and fragrances. Later in 2004
we will launch a new generation of DNS-embedded inks with Sun through their
global sales network.

Last week we also executed an agreement with Appleton, a billion dollar company
producing currency paper. Appleton and your company will jointly develop new
products to be sold through the largest packaging producer in the world.


We have a pilot program underway with a large petroleum company in South
America. Your DNA marker is being integrated into the distribution channel to
interdict annual theft in excess of $300 million.


August 18, 2004
Page 2

We have scheduled senior level meetings with HP, IBM, Pfizer, Amgen, Ford, GM,
Estee Lauder, LMVH, Nike, Sotheby's, Christies, Guernseys and others to present
you DNA products throughout the last quarter of 2004.

This month the company was successfully inducted into an elite security
coalition; the Washington DC based GTSI/InteGuard Alliance. This prestigious
group of 30 companies provides advanced security solutions to US and Foreign
Governments, the Department of Homeland Security and the Department of Defense.
As a member of the InteGuard Alliance, your company has joined an exclusive
circle that includes major corporations such as IBM, HP, Microsoft, Sun
Microsystems, Cisco, INTEL, Panasonic, and other IT (Information Technology)
leaders. Your DNA technology is being brought to the attention of these major
GTSI/InteGuard Alliance partners. Your products enhance technology solutions in
such applications as counter-terrorism, protection of key assets and critical
infrastructure, access control, identity management, high security shipping and
management and end-to-end security systems. In the foreseeable future, APDN DNA
will be protecting America's critical infrastructure and key assets. Press
releases and media attention will be implemented for all new developments.

APDN is now embarked upon a course of success that we believe will bring
significant rewards to our shareholders. We are implementing new investor
relations and public relations initiatives, and in the future we will correspond
with our shareholders on a regular basis to keep you fully apprised of
developments.

Thank you for your support of the Company.

Cordially,

/s/ Peter Brockelsby
- --------------------
    Peter Brocklesby
    President